CenterBook Partners LP Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM

CenterBook Partners LP purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,357 shares of the company’s stock, valued at approximately $613,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. MCF Advisors LLC grew its stake in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the last quarter. CWM LLC grew its position in shares of Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the last quarter. Comerica Bank increased its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period. Jones Financial Companies Lllp lifted its position in shares of Mirum Pharmaceuticals by 34.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its stake in Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after purchasing an additional 351 shares during the period.

Insiders Place Their Bets

In other news, CFO Eric Bjerkholt sold 1,053 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $101,288.07. Following the completion of the transaction, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. This represents a 2.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick J. Heron bought 131,425 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were bought at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the transaction, the director directly owned 459,010 shares in the company, valued at $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 45,136 shares of company stock valued at $4,352,029 over the last 90 days. Company insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Down 0.3%

MIRM opened at $105.16 on Friday. The company has a market capitalization of $5.40 billion, a P/E ratio of -122.28 and a beta of 0.49. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The firm’s fifty day moving average price is $90.24 and its two-hundred day moving average price is $77.77. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $107.41.

Analyst Upgrades and Downgrades

MIRM has been the topic of several recent analyst reports. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Finally, Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.17.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.